In this webinar experts will discuss the challenges cell and gene therapy innovators face and how experts resolve these barriers through adopting technology and strategy that drive an optimized plasmid production process and supply.
Making the decision to work with a consultant during the journey to a drug’s regulatory authorization can help smooth out many bumps along the way. But it’s essential that transparency, full and clear communication, and industry experience are part of the equation.
Experts explain the investment interest by pointing to several trends, spanning new therapeutics, the scale-up of new modalities, and ongoing innovation. But what will it take for these breakthroughs to realize their potential in the clinic and deliver effective treatments to patients?
In an industry where regulatory hurdles, financial barriers and clinical trial enrollment challenges all present obstacles for biopharma, how could COVID-19 vaccines reach patients so quickly? And is it possible to leverage the practices that soared vaccines through FDA emergency use and approvals processes once the pandemic is over?
In an industry where regulatory hurdles, financial barriers and clinical trial enrollment challenges all present obstacles for biopharma, how could COVID-19 vaccines reach patients so quickly? And is it possible to leverage the practices that soared vaccines through FDA emergency use and approvals processes once the pandemic is over?
While developing a drug delivered by injection, an up-and-coming biotech company ran into an all-too-common challenge: Injection site reactions and sub-optimal pharmacokinetics. An attempt to reformulate mitigated the injection site reaction, but the pharmacokinetics were still not where they needed to be.
